B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus: Longitudinal Observations

William Stohl, Samy Metyas, Soon Min Tan, Gurtej S. Cheema, Bonifacia Oamar, Dong Xu, Viktor Roschke, Youmei Wu, Kevin P. Baker, David M. Hilbert

Research output: Contribution to journalArticle

367 Citations (Scopus)

Abstract

Objective. To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE). Methods. Sixty-eight SLE patients were followed up longitudinally for a median 369 days. At each physician encounter, disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and blood was collected for determination of the serum BLyS level, blood BLyS messenger RNA (mRNA) level, and cell surface BLyS expression. Twenty normal control subjects underwent similar laboratory evaluations. Results. In contrast to the uniformly normal serum BLyS and blood BLyS mRNA phenotypes in control subjects, SLE patients displayed marked heterogeneity, with 50% and 61% of patients manifesting persistently or intermittently elevated serum BLyS and blood BLyS mRNA phenotypes, respectively. Surface BLyS expression by SLE peripheral blood mononuclear cells was also often increased. Treatment of patients who had elevated serum BLyS levels with intensive courses of high-dose corticosteroids resulted in marked reductions in serum BLyS levels, and tapering of the corticosteroid dosage often resulted in increases in serum BLyS levels. Serum BLyS levels generally correlated with anti-double-stranded DNA (anti-dsDNA) titers (in those with detectable anti-dsDNA titers), but changes in serum BLyS levels did not correlate with changes in disease activity in individual patients. Serum BLyS phenotype did not associate with specific organ system involvement. Conclusion. Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.

Original languageEnglish (US)
Pages (from-to)3475-3486
Number of pages12
JournalArthritis and Rheumatism
Volume48
Issue number12
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

B-Cell Activating Factor
Systemic Lupus Erythematosus
Serum
Phenotype
Messenger RNA
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus : Longitudinal Observations. / Stohl, William; Metyas, Samy; Tan, Soon Min; Cheema, Gurtej S.; Oamar, Bonifacia; Xu, Dong; Roschke, Viktor; Wu, Youmei; Baker, Kevin P.; Hilbert, David M.

In: Arthritis and Rheumatism, Vol. 48, No. 12, 12.2003, p. 3475-3486.

Research output: Contribution to journalArticle

Stohl, W, Metyas, S, Tan, SM, Cheema, GS, Oamar, B, Xu, D, Roschke, V, Wu, Y, Baker, KP & Hilbert, DM 2003, 'B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus: Longitudinal Observations', Arthritis and Rheumatism, vol. 48, no. 12, pp. 3475-3486. https://doi.org/10.1002/art.11354
Stohl, William ; Metyas, Samy ; Tan, Soon Min ; Cheema, Gurtej S. ; Oamar, Bonifacia ; Xu, Dong ; Roschke, Viktor ; Wu, Youmei ; Baker, Kevin P. ; Hilbert, David M. / B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus : Longitudinal Observations. In: Arthritis and Rheumatism. 2003 ; Vol. 48, No. 12. pp. 3475-3486.
@article{8fab6735ffcd4dc494aaacac1fc0ad04,
title = "B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus: Longitudinal Observations",
abstract = "Objective. To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE). Methods. Sixty-eight SLE patients were followed up longitudinally for a median 369 days. At each physician encounter, disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and blood was collected for determination of the serum BLyS level, blood BLyS messenger RNA (mRNA) level, and cell surface BLyS expression. Twenty normal control subjects underwent similar laboratory evaluations. Results. In contrast to the uniformly normal serum BLyS and blood BLyS mRNA phenotypes in control subjects, SLE patients displayed marked heterogeneity, with 50{\%} and 61{\%} of patients manifesting persistently or intermittently elevated serum BLyS and blood BLyS mRNA phenotypes, respectively. Surface BLyS expression by SLE peripheral blood mononuclear cells was also often increased. Treatment of patients who had elevated serum BLyS levels with intensive courses of high-dose corticosteroids resulted in marked reductions in serum BLyS levels, and tapering of the corticosteroid dosage often resulted in increases in serum BLyS levels. Serum BLyS levels generally correlated with anti-double-stranded DNA (anti-dsDNA) titers (in those with detectable anti-dsDNA titers), but changes in serum BLyS levels did not correlate with changes in disease activity in individual patients. Serum BLyS phenotype did not associate with specific organ system involvement. Conclusion. Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.",
author = "William Stohl and Samy Metyas and Tan, {Soon Min} and Cheema, {Gurtej S.} and Bonifacia Oamar and Dong Xu and Viktor Roschke and Youmei Wu and Baker, {Kevin P.} and Hilbert, {David M.}",
year = "2003",
month = "12",
doi = "10.1002/art.11354",
language = "English (US)",
volume = "48",
pages = "3475--3486",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - B Lymphocyte Stimulator Overexpression in Patients with Systemic Lupus Erythematosus

T2 - Longitudinal Observations

AU - Stohl, William

AU - Metyas, Samy

AU - Tan, Soon Min

AU - Cheema, Gurtej S.

AU - Oamar, Bonifacia

AU - Xu, Dong

AU - Roschke, Viktor

AU - Wu, Youmei

AU - Baker, Kevin P.

AU - Hilbert, David M.

PY - 2003/12

Y1 - 2003/12

N2 - Objective. To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE). Methods. Sixty-eight SLE patients were followed up longitudinally for a median 369 days. At each physician encounter, disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and blood was collected for determination of the serum BLyS level, blood BLyS messenger RNA (mRNA) level, and cell surface BLyS expression. Twenty normal control subjects underwent similar laboratory evaluations. Results. In contrast to the uniformly normal serum BLyS and blood BLyS mRNA phenotypes in control subjects, SLE patients displayed marked heterogeneity, with 50% and 61% of patients manifesting persistently or intermittently elevated serum BLyS and blood BLyS mRNA phenotypes, respectively. Surface BLyS expression by SLE peripheral blood mononuclear cells was also often increased. Treatment of patients who had elevated serum BLyS levels with intensive courses of high-dose corticosteroids resulted in marked reductions in serum BLyS levels, and tapering of the corticosteroid dosage often resulted in increases in serum BLyS levels. Serum BLyS levels generally correlated with anti-double-stranded DNA (anti-dsDNA) titers (in those with detectable anti-dsDNA titers), but changes in serum BLyS levels did not correlate with changes in disease activity in individual patients. Serum BLyS phenotype did not associate with specific organ system involvement. Conclusion. Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.

AB - Objective. To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE). Methods. Sixty-eight SLE patients were followed up longitudinally for a median 369 days. At each physician encounter, disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and blood was collected for determination of the serum BLyS level, blood BLyS messenger RNA (mRNA) level, and cell surface BLyS expression. Twenty normal control subjects underwent similar laboratory evaluations. Results. In contrast to the uniformly normal serum BLyS and blood BLyS mRNA phenotypes in control subjects, SLE patients displayed marked heterogeneity, with 50% and 61% of patients manifesting persistently or intermittently elevated serum BLyS and blood BLyS mRNA phenotypes, respectively. Surface BLyS expression by SLE peripheral blood mononuclear cells was also often increased. Treatment of patients who had elevated serum BLyS levels with intensive courses of high-dose corticosteroids resulted in marked reductions in serum BLyS levels, and tapering of the corticosteroid dosage often resulted in increases in serum BLyS levels. Serum BLyS levels generally correlated with anti-double-stranded DNA (anti-dsDNA) titers (in those with detectable anti-dsDNA titers), but changes in serum BLyS levels did not correlate with changes in disease activity in individual patients. Serum BLyS phenotype did not associate with specific organ system involvement. Conclusion. Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.

UR - http://www.scopus.com/inward/record.url?scp=10744224617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224617&partnerID=8YFLogxK

U2 - 10.1002/art.11354

DO - 10.1002/art.11354

M3 - Article

C2 - 14673998

AN - SCOPUS:10744224617

VL - 48

SP - 3475

EP - 3486

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -